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Differential Impairment of Glucagon Responses to Hypoglycemia,
Neuroglycopenia, Arginine, and Carbachol in Alloxan-Diabetic Mice
Bo Ahre´n, Gerald J. Taborsky Jr, and Peter J. Havel
To gain insight into the mechanisms responsible for the loss of the glucagon response to insulin-induced hypoglycemia in
type 1 diabetes, glucagon responses to 4 different stimuli were examined over 3 months of diabetes in alloxan-treated mice.
At 1, 6, and 12 weeks after alloxan (60 mg/kg), phloridzin (0.1 g/kg) was administered to overnight fasted diabetic mice to
match the glucose levels of those in nondiabetic control mice before administration of the acute stimuli. Despite the elevation
of baseline glucagon levels produced by the phloridzin treatment, the glucagon responses to insulin (2 U/kg intraperitoneally
[IP])-induced hypoglycemia was not impaired at 1 week. However, the response was reduced by greater than 60% after 6 and
12 weeks of diabetes (P < .05). In contrast, the glucagon response to arginine (0.25 g/kg intravenously [IV]) was not reduced
after 1, 6, or 12 weeks of diabetes, ruling out a generalized impairment of the A-cell responses. The glucagon response to the
neuroglucopenic agent, 2-deoxyglucose (2-DG; 500 mg/kg IV) was impaired, like that to insulin-induced hypoglycemia, after
6 and 12 weeks of diabetes (P < .05), suggesting that supersensitivity to the potential inhibitory effects of exogenous insulin
is not the mechanism responsible for the impairment. Finally, the glucagon response to the cholinergic agonist, carbachol
(0.53 mmol/kg IV), was not impaired in the diabetic animals, arguing against a defect in the A-cell’s responsiveness to
autonomic stimulation. The data suggest that the impairment of the glucagon response to insulin-induced hypoglycemia in
alloxan diabetic mice is not due to a generalized impairment of A-cell responsiveness, to desensitization by a suppressive
action of insulin, or to impairment of the A-cell response to autonomic stimuli. The remaining mechanisms which are likely
to explain the late loss of the glucagon response to insulin-induced hypoglycemia include (1) a defect in the A-cell recognition
of glucopenic stimuli, or (2) a defect in the autonomic inputs to the A cell that are known to be activated by glucopenic stimuli.
Copyright © 2002 by W.B. Saunders Company
IT IS WELL ESTABLISHED that increased glucagon secre-tion during acute hypoglycemia is an important factor for
the restoration of euglycemia.1,2 It is also established that the
glucagon response to insulin-induced hypoglycemia is im-
paired in diabetes.3-8 This impairment is of clinical importance,
since defective glucagon secretion increases the risk of severe
hypoglycemia during insulin treatment of type 1 diabetes.1 The
glucagon response to insulin-induced hypoglycemia is also
impaired in rodents with experimentally induced diabetes, al-
though the impairment occurs more rapidly than in humans.9-14
Several mechanisms have been proposed to explain the im-
paired glucagon response to insulin-induced hypoglycemia in
type 1 diabetes.15 These possible mechanisms include (1) a
generalized impairment of A-cell responses to external stimuli;
(2) a supersensitivity of the A cell to the suppressive effects of
exogenous insulin16,17; (3) an impairment of the A-cell respon-
siveness to autonomic stimuli; (4) impaired activation of the
autonomic inputs to the pancreas15; and (5) a specific defect in
the ability of the A cell5 or the islet18 to recognize and respond
to glucopenic stimuli.
Although thoroughly testing each possible mechanism is a
Herculean task, it is possible to gain significant insight into the
plausibility of certain mechanisms by examining the glucagon
response to different stimuli over time after the onset of dia-
betes. Therefore, we conducted such a study examining the
glucagon response to 4 different stimuli in alloxan-diabetic
mice at different time points after induction of insulin-deficient
diabetes. A dose of alloxan was employed (60 mg/kg intrave-
nously [IV]) which induces a stable and permanent diabetes
that does not require insulin treatment to prevent ketoacido-
sis.19 This latter point makes it unlikely that any impairment of
the glucagon responses observed would be due to hypoglyce-
mia-associated autonomic failure (HAAF), because such prior
hypoglycemia usually requires administration of exogenous
insulin.20,21 Another important factor in the study design was
that the glycemia was normalized in the diabetic mice on the
day of each study, before administration of any of the 4
glucagon stimuli. Thus, the variability in the baseline glucose
levels that could potentially confound the comparisons of the
glucagon responses between the diabetic and nondiabetic mice
was eliminated. The treatment used to acutely reverse the
diabetic hyperglycemia was phloridzin. Phloridzin reduces cir-
culating glucose through renal excretion by an insulin-indepen-
dent mechanism22 and has been used previously to normalize
glucose levels in rodent models of insulin-independent dia-
betes.23
It was first important to establish that an impairment of the
glucagon response to insulin-induced hypoglycemia actually
develops in this model of diabetes. To that end, the glucagon
response to insulin-induced hypoglycemia was examined after
1, 6, and 12 weeks of alloxan-induced diabetes. To determine
if any observed impairment in the glucagon response to insulin-
induced hypoglycemia was due to a generalized impairment of
the A cell, the glucagon response to IV administration of the
amino acid, L-arginine, was next examined. To determine if
supersensitivity to the suppressive effect of exogenous insulin
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on the A cells might be responsible for the impairment of the
glucagon response to insulin-induced hypoglycemia, the glu-
cagon response to another glucopenic stimulus, not associated
with markedly increased insulin levels, was examined. This
alternative glucopenic stimulus was the glucose analog, 2-de-
oxyglucose (2-DG), which produces intracellular glucopenia by
competing with glucose for membrane transport and intracel-
lular phosphorylation.24 The resulting central neuroglucopenia
activates the autonomic nervous system, thereby increasing
glucagon seretion, without lowering circulating glucose con-
centrations or, in alloxan-induced diabetes, increasing the ex-
posure of the A cell to insulin. Finally, to determine if the
responsiveness of the A cell to cholinergic stimulation might be
impaired, we examined the glucagon response to the cholin-
ergic agonist, carbachol.
MATERIALS AND METHODS
Animals and Study Design
Female mice of the NMRI strain were obtained from Bomholtgaard
Breeding and Research Centre, Ry, Denmark, at 4 weeks of age. The
animals were fed a standard pellet diet and tapwater ad libitum. One
week after arrival, ie, at the age of 5 weeks, animals were injected IV
with alloxan monohydrate (Sigma Chemical Co, St Louis, MO; 60
mg/kg); controls were injected with saline. The experiments were
performed at 1, 6, and 12 weeks later in conscious animals. Each
animal therefore underwent 3 experiments. The animals were not
treated with insulin during the 12 weeks of the study. The study was
approved by the Animal Ethics Committee at Lund University.
Experiments
Following an overnight fast, a blood sample was rapidly obtained
from the intraorbital, retrobulbar plexus at 8 AM. Thereafter, the dia-
betic animals were injected intraperitoneally (IP) with phloridzin (Sigma;
0.1 g/kg; dissolved in 10% dimethyl-sulfoxide [DMSO]); controls were
given an equal volume of DMSO. The injections were repeated at 9 AM,
10 AM, and 11 AM. At noon, ie, 4 hours after the first phloridzin/vehicle
injection, a new blood sample was taken and the mice were injected
with either human insulin (Actrapid, Novo Nordisk, Bagsvaerd, Den-
mark; 2 U/kg IP), the amino acid, L-arginine hydrochloride (Sigma;
0.25 g/kg IV), the glucose analog, 2-DG (Sigma; 0.5 g/kg IV), or the
cholinergic agonist, carbachol (Sigma; 0.53 mmol/kg IV). New blood
samples were then taken after 15, 30, 45, and 60 minutes (insulin
experiments) or after 2 minutes (2-DG, arginine, and carbachol exper-
iments). The doses of these agents and the 2-minute time point for
sampling after administration of 2-DG, arginine, or carbachol were
selected to achieve a rapid glucagon response, as shown in previous
experiments25-28 (Ahre´n, unpublished data). After blood sampling,
plasma was immediately separated following a centrifugation at 4°C
and stored at 220°C until analysis.
Analysis
Plasma glucagon was determined radioimmunochemically with the
use of guinea pig antiglucagon antibodies specific for pancreatic glu-
cagon, 125I-labeled glucagon as tracer, and glucagon standard (Linco
Research, St Charles, MO). Free and bound radioactivity was separated
by use of an anti-IgG (goat anti-guinea pig) antibody (Linco). The
sensitivity of the assay is 7.5 pg/mL and the coefficient of variation is
less than 9%. The antibody is specific for pancreatic glucagon and
exhibits cross-reactivity with gut-derived glucagon molecules of less
than 0.1% (Linco). Plasma insulin was determined by radioimmuno-
assay with the use of a guinea pig anti-rat insulin antibody, 125I-labeled
porcine insulin as tracer, and rat insulin as standard (Linco). Free and
bound radioactivity was separated by use of an anti-IgG (goat anti-
guinea pig) antibody (Linco). Plasma glucose concentrations were
determined with the glucose oxidase technique.
Calculations and Statistics
Means 6 SEM are shown. The area under the curve (AUC) above
baseline glucagon levels from 0 to 60 minutes after insulin adminis-
tration was calculated by the trapezoid method. Statistical analyses
were performed with the SPSS for Windows system (SPSS, Inc,
Chicago, IL). Statistical comparisons for the change in glucagon levels
in each experiment between alloxan-diabetic and control mice were
performed by the use of Student’s unpaired t test with Bonferroni’s
correction for multiple comparisons.
RESULTS
Baseline Values
Fasting plasma glucose and insulin levels before the first
administration of phloridzin or vehicle and after 4 hours of
phloridzin/vehicle treatment are shown in Table 1. Phloridzin
treatment reduced circulating glucose levels in alloxan-diabetic
mice, resulting in glucose levels similar to those in the nondi-
abetic control animals at the time of each experiment (Table 2
and Fig. 1). Plasma insulin levels were lower in alloxan-
diabetic mice than in control mice 1 week after alloxan admin-
istration, with no progressive reduction in insulin levels over
the 12-week study period.
Insulin-Induced Hypoglycemia
Plasma glucose and glucagon levels immediately before and
for 1 hour after IP insulin administration in control and phlo-
ridzin-treated alloxan-diabetic animals at 1, 6, or 12 weeks after
diabetes induction are illustrated in Fig 1. Plasma glucose
levels were reduced similarly in response to insulin adminis-
tration in control and alloxan-diabetic animals with a nadir of
approximately 1 mmol/L at 30 minutes after insulin adminis-
tration. In both control and alloxan-diabetic animals, a coun-
terregulatory glucagon response was induced with a maximal
increase observed at either 15 or 30 minutes after insulin
administration. The hypoglycemia-induced increase in gluca-
gon levels was not significantly different between control and
diabetic animals after 1 week of diabetes. However, the in-
crease in glucagon levels was smaller in the diabetic animals at
6 or 12 weeks after diabetes induction than in the controls. This
is illustrated in Fig 2, which shows the AUC in the 2 groups at
1, 6, or 12 weeks after alloxan administration. The AUC in the
diabetic animals was not significantly reduced at 1 week after
alloxan administration, but was reduced by 60% after 6 weeks
(P 5 .021) and by 70% after 12 weeks (P 5 .008). Thus, the
A-cell response to insulin-induced hypoglycemia becomes im-
paired over the course of 12 weeks of alloxan-induced diabetes
in mice.
Arginine
To determine whether there is a generalized impairment of
A-cell function in alloxan-induced diabetes or whether there is
an inability of the A cells to elicit a full glucagon response due
to the elevated baseline glucagon levels, we also examined the
glucagon responses to the amino acid, L-arginine. The glucagon
responses to arginine at 1, 6, and 12 weeks after diabetes
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induction in the mice are shown in Fig 3. There was no
difference in the glucagon response to arginine between non-
diabetic and alloxan diabetic mice at any of the time points
studied. Therefore, there is no generalized impairment of A-cell
function in alloxan-induced diabetes. Arginine increased
plasma insulin levels in controls but not in alloxan-diabetic
mice (Table 2).
2-DG
Since the impairment of the glucagon response to insulin-
induced hypoglycemia in diabetes may be due to supersensi-
tivity of the A cell to the suppressive effect of insulin, we
examined whether the glucagon response to another glucopenic
stimulus is also impaired. We thus administered the glucose
analog, 2-DG, to the mice, since the stimulation of glucagon
secretion by 2-DG is achieved in the alloxan-diabetic animals
without any concomitant increase in circulating insulin. Figure
4 shows the 2-DG–induced glucagon response at 1, 6, and 12
weeks after alloxan or saline. At 1 week, the glucagon response
to 2-DG did not differ between the diabetic and control ani-
mals, whereas after 6 or 12 weeks, the 2-DG–induced glucagon
response was impaired by approximately 60% in the diabetic
animals (P 5 .026 and P 5 .022, respectively). 2-DG increased
plasma insulin levels in controls, but not in alloxan-diabetic
mice (Table 2). Therefore, the glucagon response to 2-DG was
impaired at 6 to 12 weeks after induction of diabetes by
alloxan, like that to insulin-induced hypoglycemia.
Carbachol
Both insulin-induced hypoglycemia and 2-DG–induced neu-
roglucopenia are known to activate the parasympathetic nerves
innervating the pancreas, and to stimulate glucagon secretion
by an atropine-sensitive mechanism.6,29 To examine whether
the impairment of 2-DG—induced glucagon secretion in alloxan-
diabetic mice might be due to an impairment of the A cells
response to cholinergic activation, we administered the cholin-
ergic agonist, carbachol, at 1, 6, and 12 weeks after diabetes
induction. As is seen in Fig 5, the glucagon response to carba-
chol was larger in alloxan-diabetic animals when compared
with the controls after 1, 6, or 12 weeks after diabetes (P , .05
or less). Carbachol increased plasma insulin levels in controls
but not in alloxan-diabetic mice (Table 2). Therefore, the
responsiveness of the A cells to cholinergic activation is not
reduced in alloxan-induced diabetes.
Table 1. Plasma Glucose and Insulin Levels After an Overnight Fast and After an Additional 4-Hour Treatment of Control Animals With
Vehicle or of Alloxan (60 mg/kg IV)-Diabetic Animals With Phloridzin
1 Week 6 Weeks 12 Weeks
Controls Alloxan-Diabetes Controls Alloxan-Diabetes Controls Alloxan-Diabetes
No. of animals 44 44 44 42 38 36
Fasting glucose (mmol/L) 4.8 6 0.3 15.7 6 1.3* 3.9 6 0.4 12.6 6 1.4 4.0 6 0.3 14.6 6 1.7*
Fasting insulin (pmol/L) 152 6 32 36 6 5* 146 6 7 32 6 3* 114 6 11 38 6 6*
Post vehicle (controls) or
phloridzin (diabetics)
glucose (mmol/L) 3.5 6 0.2 3.6 6 0.2 (NS) 3.5 6 0.3 3.3 6 0.4 (NS) 3.8 6 0.3 3.7 6 0.4 (NS)
Post vehicle (controls) or
phloridzin (diabetics)
glucagon (pg/mL) 51 6 3 245 6 30* 52 6 5 586 6 93* 53 6 4 696 6 101*
NOTE. Means 6 SEM are shown.
Abbreviation: NS, not significant.
*Probability level of random difference between groups, P , .001.
Table 2. Plasma Glucose Levels After an Overnight Fast Before and After IV Administration of 2-DG (0.5 g/kg), Arginine (0.25 g/kg), or
Carbachol (0.53 mmol/kg), and the Insulin Response to 2-DG, Arginine or Carbachol
1 Week 6 Weeks 12 Weeks
Controls Alloxan-Diabetes Controls Alloxan-Diabetes Controls Alloxan-Diabetes
Glucose (mmol/L)
Before 2-DG 3.3 6 0.2 4.2 6 0.3 3.6 6 1.0 3.5 6 1.0 4.1 6 0.4 3.5 6 0.6
Before arginine 4.1 6 0.2 4.0 6 0.8 3.5 6 0.1 2.5 6 0.3 4.1 6 0.3 3.7 6 0.8
After arginine 7.6 6 0.4 6.9 6 1.1 6.9 6 0.7 2.7 6 0.4 5.4 6 0.4 4.2 6 0.9
Before carbachol 4.1 6 0.3 3.3 6 0.3 4.1 6 0.4 3.6 6 0.7 4.5 6 0.2 4.6 6 1.5
After carbachol 7.6 6 0.6 5.5 6 0.7 6.8 6 0.6 4.6 6 1.2 5.5 6 0.5 4.6 6 1.2
Insulin response (pmol/L)
2-DG 277 6 96 45 6 17 169 6 74 19 6 15 371 6 60 29 6 23
Arginine 338 6 85 83 6 32 258 6 76 22 6 8 584 6 154 99 6 81
Carbachol 330 6 121 133 6 90 396 6 120 27 6 10 318 6 130 27 6 17
NOTE. Experiments were performed after 4-hour treatment of control animals with vehicle and of alloxan (60 mg/kg IV)-diabetic animals with
phloridzin to match glucose levels. Glucose levels after 2-DG are not interpretable because 2-DG partially crossreacts with glucose oxidase in the
glucose assay. Means 6 SEM are shown. There were 8 to 12 animals in each group.
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DISCUSSION
In this study we used the alloxan diabetic mouse to examine
the time-course of the impairment of the glucagon response to
insulin-induced hypoglycemia after the induction of diabetes.
In addition, glucagon responses to other stimuli were examined
to gain insight into the mechanism(s) responsible for this im-
pairment. Since these glucagon responses are influenced by the
baseline glucose levels present before the acute stiumlus,18,30 it
is important to match the glucose levels when comparing
glucagon response between diabetic and nondiabetic animals.
In this study, glucose concentrations were matched by admin-
istering phloridzin to the alloxan-diabetic mice. After acutely
Fig 1. Plasma levels of glu-
cose and glucagon before and
after IP administration of insulin
(2 U/kg) to overnight fasted con-
trol and alloxan-diabetic mice at
1, 6, or 12 weeks after adminis-
tration of alloxan (60 mg/kg). Al-
loxan-diabetic animals had been
treated with phloridzin 4 hours
before the experiments, to match
glucose levels at the time of insu-
lin administration. Means 6 SEM
are shown. There were 10-12
animals in each group. Asterisks
indicate the probability level of
random difference between the
groups at the indicated time pe-
riods. *P < .05; **P < .01.
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normalizing the baseline glucose levels with phloridzin injec-
tions, insulin produced a marked degree of hypoglycemia (;1
mmol/L), which was equivalent in control and alloxan diabetic
animals. The hypoglycemia in turn induced an increase in
circulating glucagon concentrations in both the diabetic and the
nondiabetic animals, which was maximal at 15 to 30 minutes
after insulin administration. To compare the glucagon re-
sponses between different groups at different times, we calcu-
lated the net increase in glucagon levels by subtracting the
basal levels from the stimulated levels in each individual
mouse. The conclusions are therefore based on the assumption
that the increment over baseline concentrations is the appropri-
ate index of the glucagon response to hypoglycemia and an
important determinant of counterregulatory response, even
when basal glucagon levels are elevated. However, since our
study was focused on glucagon secretion, we did not follow the
entire glucose counterregulatory response. Therefore, this study
does not allow conclusions about the physiological action of
the glucagon response in diabetic versus control mice. The
study does show that while the glucagon response to insulin-
induced hypoglycemia was not different between the 2 groups
after 1 week of diabetes, there was an approximately 60%
reduction of this glucagon response after either 6 or 12 weeks
of diabetes. This result agrees with a previous longitudinal
study in streptozotocin-diabetic rats showing a normal gluca-
gon response to hypoglycemia after 1 week of diabetes, but a
substantial impairment of the glucagon response after 6 weeks
of diabetes.12 Similarly, in cross-sectional studies, impaired
glucagon responses to insulin-induced hypoglycemia have also
been reported in humans,3-8 dogs,31 and rats9,13,14,32 after dia-
betes of various durations, although the development of the
impairment appears to occur more rapidly in rodents than in
humans.
Several mechanisms have been proposed to account for the
impairment of the glucagon response to insulin-induced hypo-
glycemia in type 1 diabetes, including (1) a generalized im-
pairment of A-cell function, (2) a supersensitivity of the A cell
to the suppressive effect of exogenous insulin, (3) an impaired
A-cell responsiveness to autonomic stimulation, (4) an impair-
ment of A-cell responsiveness to glucopenic stimulation and
(5) an impaired activation of the autonomic inputs to the a cell
during glucopenia.5,15-18
To test for a generalized impairment of A-cell function, we
administered the amino acid, L-arginine. We found that the
glucagon response to arginine in nondiabetic control animals
was not different than that found in alloxan-diabetic mice,
regardless of the duration of diabetes. Therefore, in this study
alloxan-induced diabetes does not appear to be associated with
a generalized defect in A-cell responsiveness. This finding is
similar to that found in human diabetes mellitus of long dura-
tion: type 1 diabetic patients have a severe impairment of their
glucagon response to insulin-induced hypoglycemia yet retain a
normal glucagon response to arginine.5 Thus, alloxan-diabetic
mice model a major feature of glucagon secretion seen in
human type 1 diabetes.
Another form of generalized impairment could possibly be
caused by the elevated baseline glucagon levels seen after
phloridzin treatment of alloxan-diabetic mice. This basal hy-
perglucagonemia may be caused by increased number of glu-
cagon cells, which has been demonstrated in alloxan-diabetic
mice,33 insulin deficiency, or the reduction in glucose induced
by phloridzin. High glucagon levels have also been reported in
streptozotocin-diabetic rats.34 Thus it is possible that the high
baseline levels, particularly those seen after 12 weeks of dia-
betes, might have limited the magnitude of the calculated
Fig 3. Increase in plasma glucagon 2 minutes after IV administra-
tion of arginine (0.25 g/kg) in overnight fasted control and alloxan-
diabetic mice at 1, 6, and 12 weeks after administration of alloxan (60
mg/kg). Alloxan-diabetic animals had been treated with phloridzin
before the experiments, to match the glucose levels at the time of
arginine administration. Means 6 SEM are shown. There were 8-10
animals in each group.
Fig 2. The 60-minute area under the glucagon curve (AUCglucagon)
after IV insulin (2 U/kg) in overnight fasted control and alloxan-
diabetic mice at 1, 6, or 12 weeks after administration of alloxan (60
mg/kg). Alloxan-diabetic animals had been treated with phloridzin
before the experiments, to match glucose levels at the time of insulin
administration. Means 6 SEM are shown. There were 10 animals in
each group. Asterisks indicate the probability level of random differ-
ence between the groups. *P < .05, **P < .01.
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glucagon response to acute stimulation, if the glucagon peak
reached the maximal glucagon level obtainable. However,
since the absolute peak glucagon levels were higher after
arginine (or carbachol) than after insulin (or 2-DG) and since
the baseline glucagon levels were similar before these acute
stimuli, then the calculated glucagon response to insulin-in-
duced hypoglycemia does not seem to be limited by the ele-
vated baseline glucagon levels observed at 12 weeks of dia-
betes.
The second possible mechanism for the impairment of the
glucagon response to insulin-induced hypoglycemia is the de-
velopment of A-cell supersensitivity to the suppressive effects
of exogenous insulin. We therefore examined the glucagon
response to a glucopenic agent, 2-DG, which does not increase
the circulating insulin level in alloxan-diabetic mice. Since we
found that the glucagon response to 2-DG was also impaired at
6 and 12 weeks of diabetes we suggest that neither impairment
is due to supersensitivity of the A cell to the suppressive action
of exogenous insulin.
To test the possibility that the impaired glucagon response
to insulin-induced hypoglycemia in the alloxan-diabetic mice
might be caused by loss of sensitivity to direct stimulation by
autonomic inputs, we administered the cholinergic agonist,
carbachol. Carbachol is a potent agent stimulating glucagon
secretion in mice through activation of muscarinic receptors:
carbachol-stimulated glucagon secretion in mice is prevented
by muscarinic antagonism.24,25,26,35 Surprisingly, we found that
carbachol-stimulated glucagon secretion was augmented in this
particular species and duration of diabetes, suggesting super-
sensitivity to, rather than impairment of, direct cholinergic
stimulation of the A cell in these animals. These data argue
against an impaired responsiveness of the A cell to autonomic
stimulation as a cause of the impaired glucagon response to
insulin-induced hypoglycemia.
One possible mechanism that cannot be ruled out by the
present studies is an impairment of the A cell’s ability to
respond to direct glucopenic stimulation. Such a mechanism is
consistent with our finding of an impaired glucagon response to
the 2 glucopenic stimuli, insulin-induced hypoglycemia and
2-DG, at 6 and 12 weeks of diabetes, as well as unimpaired
glucagon responses to the nonglucopenic stimuli, arginine and
carbachol. However, our previous studies have shown that
ganglionic blockade nearly eliminated the glucagon response to
insulin-induced hypoglycemia in normal mice,35 suggesting
that the direct glucopenic stimulation of the A cell produces
only a minor increase of glucagon secretion. It is therefore
unlikely that the impairment of the ability of the A cell to
respond to direct glucopenic stimulation is responsible for the
marked impairment of the glucagon response to insulin-in-
duced hypoglycemia observed in diabetes.
A defective glucagon response to insulin-induced hypogly-
cemia in diabetes might also be explained by disturbed islet
cell-cell interactions.15 Thus, if inhibition of endogenous in-
sulin secretion after administration of exogenous insulin is a
stimulus for glucagon secretion, then alloxan-induced destruc-
tion of the islet B cells could impair the glucagon response to
insulin-induced hypoglycemia. However, a previous study in
humans has shown that prior marked suppression of endoge-
nous insulin secretion does not potentiate the glucagon re-
sponse to hypoglycemia,36 which argues against a major role
for inhibition of endogenous insulin secretion.
Further, since 2-DG stimulates insulin secretion in nondia-
betic mice, suppression of endogenous insulin cannot play a
significant role in the glucagon response to this glucopenic
stimulus; therefore defects in B-/A-cell interactions in the al-
loxan-diabetic mice cannot explain its impairment. Another
potential mechanism for the reduction of the glucagon response
Fig 4. Increase in plasma glucagon 10 minutes after IV adminis-
tration of 2-DG (0.5 g/kg) in overnight fasted control and alloxan-
diabetic mice at 1, 6, and 12 weeks after administration of alloxan (60
mg/kg). Alloxan-diabetic animals had been treated with phloridzin
before the experiments, to match glucose levels at the time of 2-DG
administration. There were 10-12 animals in each group. Asterisks
indicate the probability level of random difference between the
groups. **P < .01.
Fig 5. Increase in plasma glucagon 2 minutes after IV administra-
tion of the cholinergic agonist, carbachol (0.53 mmol/kg) in overnight
fasted control and alloxan-diabetic mice at 1, 6, and 12 weeks after
administration of alloxan (60 mg/kg). Alloxan-diabetic animals had
been treated with phloridzin before the experiments, to match the
glucose levels at the time of carbachol administration. Means 6 SEM
are shown. There were 8-10 animals in each group. Asterisks indicate
the probability level of random difference between the groups and
between the different time period within the groups; *P < .05,
**P < .01.
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to neuroglucopenic stimuli is an impairment in the activation of
the autonomic inputs to the A cell. Indeed, in nondiabetic mice,
activation of the autonomic inputs to the A cell has been
demonstrated to be the major mediator of the glucagon re-
sponse to both insulin-induced hypoglycemia and 2-DG–in-
duced glucopenia since blockade of the ganglionic transmission
involved in these autonomic pathways abolishes 90% of these
responses.35 Thus it remains possible that 6 to 12 weeks of
diabetes can impair the autonomic activation normally elicited
by either insulin-induced hypoglycemia or 2-DG resulting in
the impaired glucagon response to each. Support for this hy-
pothesis is provided by earlier studies in streptozotocin treated
rats which demonstrated a parallel reduction in the autonomic
activation and the glucagon response to insulin-induced hypo-
glycemia with increasing duration of diabetes.12,13 Measure-
ments of plasma epinephrine, as an index of the sympathoad-
renal response, and plasma pancreatic polypeptide, as an index
of the pancreatic parasympathetic response,29 in the present
study would have provided direct evidence bearing on this
potential autonomic mechanism. Unfortunately, the limited
blood volume of these mice precluded such measurements. The
only evidence in the present study for an autonomic impairment
is very indirect: the glucagon response to carbachol is exag-
gerated in diabetic. This impairment could be secondary to islet
parasympathetic denervation. Thus, although the known auto-
nomic mediation of the glucagon response to insulin-induced
hypoglycemia and 2-DG in nondiabetic mice coupled with the
parallel reduction in the glucagon response to these same
stimuli with increasing duration of diabetes in alloxan treated
mice suggests that an autonomic impairment might mediate the
impaired glucagon response to insulin-induced hypoglycemia;
further studies are needed to definitely implicate this as the
dominant mechanism response for the loss of the A-cell re-
sponse.
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